00, suggesting a possible upside of. 89 $2. 72%. Theratechnologies Inc. , that crews have been mobilized to prepare for the 2022 exploration program at the Treaty Creek property, located in the heart of the. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. Stockhouse. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. 1300 (+9. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. Free cash flow. 65 per cent to C$1. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on. $30. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. ET. We also use them to share usage. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. (“Theratechnologies”) with the Securities and Exchange Commission (the. By continuing to use our service, you agree to our use of cookies. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. stock price gained 1. During the last trading day the stock fluctuated 4. Cookies are used to offer you a better browsing experience and to analyze our traffic. Revenues have been growing at an average rate of 10. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. Stockhouse. Find more information. stock news by MarketWatch. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. NCU. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. We also use them to share usage. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. Theratechnologies Announces 1-for-4 Reverse Stock Split. 40%. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. We also use them to share usage information with our partners. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Microsoft to invest $500M in Quebec AI economy. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. By continuing to use our service, you agree to our use of cookies. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. stock news by MarketWatch. Theratechnologies, Inc. 68 to a day high of $1. Cookies are used to offer you a better browsing experience and to. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. For investor inquiries: Leah Gibson. Cookies are used to offer you a better browsing experience and to analyze our traffic. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. By continuing to use our service, you agree to our use of cookies. However, it did not meet the equivalence limits of 0. 22M. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Montréal, Québec, Canada . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Oct. We currently market prescription products for people with HIV in the United States. communications@theratech. ET. Theratechnologies Stock Price, News and Company Updates. - 2023 Q3 positive adjusted EBITDA to be. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical. 86 million for the quarter. MONTREAL, Oct. Get the latest Sernova Corp (SVA) real. BioSyent then managesthese products through the regulatory process and product registration (approval); and once approved, BioSyent markets these products throughout Canada. 8. Stock analysis for Theratechnologies Inc (TH:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. 25. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. By continuing to use our service, you agree to our use of cookies. 2. Theratechnologies (TH) and partners contributed $2 million for a research project for a new treatment for metastatic cancer. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. By continuing to use our service, you agree to our use of cookies. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. D. During the last trading day the stock fluctuated 12. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 04) earnings per share (EPS) for the quarter. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 514-336-7800. Cookies are used to offer you a better browsing experience and to analyze our traffic. communications@theratech. (2022-04-27 | TSX:TH) Theratechnologies to Focus Its Commercialization Activities on the North American Territory. L. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. Company Type For Profit. com uses cookies on this site. 75. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. 22, 2023 /CNW/ - Northwest Healthcare Properties Real Estate Investment Trust (the "REIT" or "Northwest") (TSX: NWH. It is the Company’s proprietary. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. com uses cookies on this site. 75%. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. The reported ($0. The webinar will also address system-level barriers and present real-world. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or. 's motion for leave to commence. By Nick Paul Taylor Jul 12, 2023 8:57am. com uses cookies on this site. T. By continuing to use our. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. Theratechnologies Inc. . 57%) Q1 2020 Earnings Call. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. Vice President, Communications and Corporate Affairs. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. R. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Gary Littlejohn Stockhouse. By continuing to use our service, you agree to our use of cookies. Stockhouse. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. (CSE: KOG) (" KO Gold " or the " Company ") is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange (CSE) effective at the open of business on Wednesday, October 11, 2023, under the symbol " KOG ". Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon;. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. MONTREAL, Sept. 4. 25 to $1. com uses cookies on this site. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. By continuing to use our service, you agree to our use of cookies. M. 521. Browse posts by Sector and Subsector. About Us | Theratechnologies Inc. stock price gained 6. Cookies are used to offer you a better browsing experience and to analyze our traffic. . MONTREAL, Nov. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. Learn why it. com uses cookies on this site. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. communications@theratech. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. -4. Following the release, Knight will hold a conference call and audio webcast. S. com uses cookies on this site. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. Further. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. 00 in the next twelve months. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. We also use them to share usage. GlobeNewswire. Stockhouse. Theratechnologies develops and commercializes innovative therapies. Biopharmaceutical company Theratechnologies Inc. See a list of the most recent Stock Forum posts on Stockhouse. MONTREAL, Oct. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. View real-time stock prices and stock quotes for a full financial overview. com uses cookies on this site. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. 05M. com uses cookies on this site. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 5%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 35 as of 10:41 a. licensed the product from TaiMed Biologics, Inc. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. Theratechnologies Inc. Conjugating the short peptide with various anti-cancer agents allows for. T. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. BioSyent is continuously looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. MONTREAL, Oct. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. com. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. 10% most volatile stocks in CA Market. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. (TH. This news release constitutes a. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. MONTREAL, Dec. MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. T. (TH. RESSOURCES. View real-time stock prices and stock quotes for a full financial overview. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . 617-356-1009. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. Phone Number (514) 336-7800. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American. com uses cookies on this site. com uses cookies on this site. 08 (+6. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. 00%. com. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. FDA for its IV push form of administration of Trogarzo. Senior Director, Investor Relations. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. B2Gold Declares Fourth Quarter 2023 Dividend. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. Read More. Company Participants. Stockhouse. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. 1M. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Theratechnologies Inc. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected]%) S&P 500. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. Theratechnologies. com. lgibson. By continuing to use our service, you agree to our use of cookies. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. (2013-04-03 | TSX:TH) Theratechnologies Inc. 9 million and US$19. MONTREAL, Aug. 66% compared to the previous year's 69. T. Consensus forecasts updated Jul 21. 8 and 1. Proceeds to Be Used to Redeem All of the Outstanding 5. 5000 0. is a speaker and consultant of Theratechnologies. The firm offers its product under the brand name of. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. By continuing to use our service, you agree to our use of cookies. Stockhouse. com uses cookies on this site. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. 1-514-336-7800. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. Montreal-based biopharmaceutical company Theratechnologies Inc. Gary Littlejohn. is an employee of TaiMed Biologics USA, Inc. stock news by MarketWatch. TH | September 5, 2023. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. - On track to meet FY2022. WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. Jours fériés des marchés. Market Cap. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. Stockhouse. We also use them to share. is a pharmaceutical company. com uses cookies on this site. TH | February 28, 2023. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. View real-time stock prices and stock quotes for a full financial overview. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH | May 19, 2023. CA, an investment chat community for Canada's small cap marketsTheratechnologies is currently analyzing data and preparing responses to questions received from the FDA. 24 million, 48. Theratechnologies Inc. 17. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. TH | February 28, 2023. TH | Complete Theratechnologies Inc. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. (THTX) NasdaqCM - NasdaqCM Real Time Price. View analysts price targets for THTX. 49%) At close: 04:00PM EST 1. The business had revenue of $27. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. Further. By continuing to use our service, you agree to our use of cookies. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. 6. Senior Director, Investor Relations. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. com. 69, 1. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. By continuing to use our service, you agree to our use of cookies. La Bourse de Toronto a perdu. US Headquarters. com uses cookies on this site. 67% from the latest price. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. , alpha and beta) for all equities such as Theratechnologies. 5% workforce reduction. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. 63. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV).